Main Page

• HYVET published: This randomized, placebo-controlled trial demonstrated that treatment of stage II hypertension in patients over 80 years of age reduced the incidence of stroke and all cause mortality.

April 23, 2008: CoStar Drug Eluting Stent is not Non-inferior to TAXUS Drug Eluting Stents

• The CoStar (Cobalt Chromium Stent With Antiproliferative for Restenosis) II trial demonstrates that the CoStar drug eluting stent is not non-inferior to Taxus drug eluting stent based on the angiographic and clinical outcome analyses at 9 months.

April 1, 2008: High dose tirofiban and clopidogrel are safe and effective in the ON-TIME-2 trial

• The ON-TIME-2 investigators demonstrated that the early administration of high dose tirofiban together with 600mg of clopidogrel is safe and effective among patients with acute ST segment elevation myocardial infarction undergoing PCI.

April 1, 2008: Implantation of skeletal myoblasts into scarred myocardium improves symptoms but not heart function

• The SEISMIC study demonstrates that administration of skeletal myoblast improves symptoms in patients with heart failure with no effect on left ventricular function and dimensions.

April 1, 2008: Reloading With Clopidogrel Improves Clinical Outcomes in Patients with Acute Coronary Syndromes: ARMYDA-RELOAD

• Results from the ARMYDA-RELOAD trial demonstrate improved clinical outcomes when patients with acute coronary syndromes already on clopidogrel are administered an additional 600mg prior to PCI but not for patients with stable angina.

April 1, 2008: MEND-CABG II trial does not suggest improved outcomes with the novel drug MC1 in patients undergoing high risk coronary artery bypass surgery

• A novel drug MC-1 used during coronary artery bypass surgery (CABG) does not result in improved cardiovascular outcomes.

April 1, 2008: ExoSeal® Vascular Closure Device is safe and effective

• Results from the ECLIPSE trial demonstrate the superiority of the ExoSeal® Vascular Closure Device compared to manual compression in reducing both the time to hemostasis and the time to ambulation following intervention.

April 1, 2008: The ASTRAL Trial Demonstrates Angioplasty and Stenting Offer No Benefit Over Medical Therapy in Patients with Renal Arterial Stenoses

• Results from the ASTRAL trial demonstrate that there were no improvements in kidney function, blood pressure control, or rates of major cardiovascular illness in patients who receives catheter-based interventions for renal artery stenosis compared with those treated with medical therapy alone.

April 1, 2008: Standard Physician Care for Heart Failure is Just as Effective as and Less Expensive Than a Home Monitoring System

• The Heart Failure Home Care (HFHC) trial demonstrates that HF patients receiving standard follow-up care from a physician have just as good of a clinical result and a better economic outcome than those using a home-monitoring interactive system.

April 1, 2008: Similar nephrotoxic effects with iodixanol and iomeprol in the CONTRAST trial

• The CONTRAST trial demonstrates that the nephrotoxic effects are similar with the iso-osmolar contrast media (iodixanol 320) versus low-osmolar contrast media (iomeprol 350) in patients with impaired renal function undergoing percutaneous coronary intervention.

April 1, 2008: Atrial tachyarrhythmia burden ≥5.5h in a day doubles the risk for thromboembolism in the TRENDS study

• Device-detected atrial fibrillation (AF), a commonly diagnosed cardiac arrhythmia, may increase the risk of stroke, even in brief AF episodes, according to the TRENDS study presented today at ACC 08.

April 1, 2008: The EVEREST trial suggests MitraClip® for mitral regurgitation is effective

• Percutaneous mitral valve repair with the Mitraclip® device for functional mitral regurgitation is effective with low major adverse events and significant reverse remodeling at one year in the initial EVEREST cohort.

April 1, 2008: Rimonabant does not reduce atherosclerosis progression in STRADIVARIUS

• Treatment of patients with abdominal obesity with rimonabant reduces body weight and waist circumference but not atherosclerosis progression.

April 1, 2008: Automated External Defibrillators offer no benefit in cardiac arrests that occur at home in the HAT trial

• Results from the HAT trial demonstrate that survival rates did not improve among patients with access to a home AED compared with patients with only an EMS call and a companion with CPR training.

April 1, 2008: Cardiac Resynchronization Therapy and Optimal Medical Therapy May Reverse Left Ventricular Remodeling in the REVERSE trial

• Cardiac resynchronization therapy (CRT) along with optimal medical therapy (OMT), may reverse left ventricular remodeling in patients with mild or no heart failure symptoms according to the REVERSE study.

April 1, 2008: Insertable Loop Recorder Tracks Cardiac Arrhythmias Following Acute Myocardial Infarction

• Results of the CARISMA trial demonstrate that the insertable loop recorders (ILR) can document cardiac arrhythmias following myocardial infarction.

March 31, 2008: Telmisartan is as effective and safe as ramipril in patients at high risk for vascular events: Results from the ONTARGET trial

• The ONTARGET study suggests that the angiotensin receptor blocker, telmisartan is effective and safe in patients with vascular disease and high-risk diabetes compared with ramipril.

March 31, 2008: Treatment of hypertension with indapamide with or without perindopril is beneficial in the elderly: Results from the HYVET study

• Results of the HYpertension in the Very Elderly Trial (HYVET) demonstrate a benefit in the antihypertensive treatment of persons at least 80 years old with or without perindopril.

March 31, 2008: Cardiovascular risk increases with incremental doses of celecoxib

• Pooled data from a six-study analysis recommends the lowest dose possible of celecoxib for patients who derive benefit from the drug.

March 31, 2008: Dual therapy better than monotherapy to treat hypertension in the ACCOMPLISH trial

• The interim results from the ACCOMPLISH trial demonstrated that patients with hypertension and at high risk for CV complications experienced 20% fewer events with a combination of an ace inhibitor and calcium channel blocker.

March 31, 2008: Pioglitazone Prevents Progression of Coronary Atherosclerosis in Diabetic Patients With Coronary Artery Disease: Results of the PERISCOPE Trial

• Results of the PERISCOPE trial reveal that pioglitazone slows progression of plaque in type 2 diabetic patients with coronary artery disease in comparison to glimepiride.

March 31, 2008: Rosuvastatin reduces coronary artery disease progression over time in the ASTEROID trial

• Results of the ASTEROID trial demonstrates that treatment with rosuvastatin may promote atherosclerosis regression in patients with coronary artery disease (CAD).

March 31, 2008: The GENESIS Trial Demonstrates Disappointing Results With Pimecrolimus Eluting Stents

• Results from the GENESIS trial demonstrate that patients treated with CORIO™ (Pimecrolimus-eluting) stents had worse outcomes compared with individuals treated with SYMBIO™ (dual drug delivery of Pimecrolimus and Paclitaxel) stents or the CoStar® (Paclitaxel-eluting) stents.

March 31, 2008: PEPCAD II ISR study suggests that drug eluting balloons are safe and effective compared with drug eluting stents in treating in-stent restenosis

• Paclitaxel-eluting balloons are effective in reducing late lumen loss and 12 month major adverse cardiac events (MACE) compared with drug eluting stents.

March 31, 2008: The Efficacy of XIENCE V Stent over Taxus Stent Decreases with Time: Results from the SPIRIT II study

• The 2-year results of the SPIRIT II study demonstrate no significant difference between the outcomes obtained from implantation of the XIENCE V everolimus-eluting stent or the TAXUS paclitaxel-eluting stent.

March 31, 2008: Long Term Adherence to Clopidogrel and Late Adverse Cardiac Events after Off-Label Use of Sirolimus-Eluting Stents: Results of the MATRIX Registry

• Results from the MATRIX Registry, a large community-based registry consisting of patients who were treated with drug-eluting stents (DES), were presented today at the SCAI-i2 summit Annual Scientific Sessions in Chicago by Dr. George Dangas of Columbia University Medical Center.

March 31, 2008: Left main stenting is associated with similar rates of death, Q wave myocardial infarction and stroke compared with CABG at 3-year follow-up

• A non-randomized study from Korea demonstrate no significant difference in mortality rate or the composite risk of death, Q-wave myocardial infarction or stroke among patients undergoing stenting or surgery for unprotected left main stem disease.

March 31, 2008: Excel biodegradable stents are safe and effective: Results from the CREATE trial

• The 12 month clinical outcome of a prospective multicenter registry of Excel™ biodegradable polymer sirolimus eluting stents suggests that these stents are safe and effective in the “real world” population.

March 30, 2008: Drug eluting stents are associated with reduced mortality in patients with myocardial infarction at two years

• Investigators from Boston demonstrated that the use of drug-eluting stents is associated with reduced mortality at two years compared with bare metal stents among patients with an acute infarct.

March 30, 2008: High Dose Tirofiban is similar to Abciximab in reducing Major Adverse Cardiac Events

• The Multistrategy study demonstrates that high dose tirofiban is non-inferior to abciximab during PCI for acute myocardial infarction and the use of sirolimus eluting stents reduces major adverse cardiac events.

March 30, 2008: Abciximab in addition to a high loading dose of clopidogrel does not improve outcomes in STEMI patients: Results from the BRAVE-3 Trial

• Investigators from Germany demonstrate that dual therapy with high loading dose of clopidogrel (600 mg) and intravenous abciximab does not improve outcomes in ST-elevation myocardial infarction (STEMI) patients compared with clopidogrel therapy alone.

March 30, 2008: Removal of debris from the coronary arteries does not improve outcomes: Results from the A-F study

• Vascular protection in high risk non-ST elevation acute coronary syndromes in the Angioplasty Balloon-associated Coronary Debris and the EZ Filter-wire (A-F) randomized, controlled trial did not improve cardiovascular outcomes compared with conventional PCI.

March 30, 2008: Thrombus aspiration in patients with ST elevation myocardial infarction improves mortality at 1 year in the TAPAS trial

• Researchers from the Netherlands demonstrate that thrombus aspiration during coronary angioplasty for acute myocardial infarction improves one year mortality compared with conventional PCI.

March 30, 2008: Early Transfer of AMI Patients for PCI improves cardiovascular outcomes in the TRANSFER-AMI study

• The TRANSFER-AMI study demonstrates improved cardiovascular outcomes with early PCI following the administration of pharmacotherapy in patients presenting to a non-PCI treatment center with acute myocardial infarction (AMI).

March 29, 2008: Bivalirudin is no better than heparin in patients pretreated with clopidogrel undergoing PCI: Results from the ISAR-REACT-3 trial

• Investigators from Germany demonstrated that bivalirudin is not superior to unfractionated heparin (UFH) among stable patients pretreated with 600 mg of clopidogrel undergoing PCI.

March 29, 2008: Culotte is better than crush for bifurcation lesions: Results from the Nordic Stent Technique study

• Eight month angiographic follow-up in patients randomized to crush or culotte bifurcation stenting demonstrates that culotte technique might be better with reduced side branch restenosis rates.

March 29, 2008: Percutaneous Coronary Interventions can be performed in centers without on-site cardiac surgical back-up

• An analysis from the National Cardiovascular Data Registry (NCDR) demonstrates that PCI can be performed safely and successfully at medical facilities without on-site cardiac surgical back-up.

March 29, 2008: High recurrence rate of stent thrombosis after the first event: Results from the Dutch Stent Thrombosis Registry

• Results from the Dutch Stent Thrombosis study demonstrate that the implantation of an additional stent during emergency treatment of the initial stent thrombosis is among the strongest predictors of recurrent stent thrombosis.

March 29, 2008: TRITON-TIMI 38 stent analysis demonstrates that prasugrel is better than clopidogrel in reducing the incidence of early and late stent thrombosis

• The TRITON-TIMI 38 stent study demonstrates that prasugrel is better than clopidogrel in reducing the incidence of early and late stent thrombosis in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

March 29, 2008: Platelet monitoring can improve outcomes following PCI among clopidogrel resistant patients

• Investigators from France demonstrate that platelet monitoring of clopidogrel response using VASP phosphorylation index decreases the rate of major adverse cardiovascular events in patients with clopidogrel resistance.

March 28, 2008: A meta-analysis of over 180,000 patients suggests that drug eluting stents are safe for both on-label and off-label use

• The results of this meta-analysis were presented by Dr. Ajay Kirtane from the Cardiovascular Research Foundation (CRF), New York at the CRF Drug-Eluting Stent (DES) symposium in Chicago tonight.

More News: Click on one of the links below for more news

All News Articles

Acute Coronary Syndromes | Biomarker | Cardiovascular Imaging | CT Surgery | Diabetes | Electrophysiology | General Cardiology | Guidelines | Health Policy | Heart Failure | Hypertension | Interventional | Peripheral Arterial Disease | Prevention | Valvular Heart Disease |

Allergy | Anesthesiology | Cardiology | Dermatology | Ear, Nose & Throat | Endocrinology & Metabolic Disease | Emergency Medicine | GI | Genetics | Hematology | Infectious Disease | Musculoskeletal | Neurology | Nutrition | ObGyne | Oncology | Ophthalmology | Overdose & Toxicology | Pathology | Pediatrics | Psychiatry | Pulmonary | Radiology | Renal & GU | Rheumatology & Autoimmune | Surgery | Transplant

Contents by Individual Disease | by Differential Diagnosis | by Signs and Sx | by Lab Tests | Drug

WikiDoc Medical School Curriculum: Anatomy | Biochemistry | Biostatistics | Developmental Biology | Epidemiology | Histology | History | Immunology | Medical Ethics | Microbiology | Molecular Biology | Nephrology | NIH | Organic Chemistry | Pharmacology | Physiology | Public Health |

Cardiology | Dermatology | Ear, Nose & Throat | Endocrinology and Metabolism | Emergency Medicine | GI | Genetics | Ob Gyne | Hematology | Infectious Disease | Musculoskeletal & Ortho | Neurology | Nutrition | Oncology | Opthalmology | Pathology | Psychiatry | Pulmonary | Renal & GU | Rheumatology & Autoimmune

Click Here For WikiPatient

WikiPatient Home Page

Care Centers

Look up a Drug & its side effects

Report a side effect to the FDA at MedWatch

What Was My Doctor Talking About? Watch world experts explain procedures and treatments in language that you can understand

Look up Signs and Symptoms

Click here to put WikiDoc on your iPod